FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2169072424> ?p ?o ?g. }

• W2169072424 endingPage "40" @default.
• W2169072424 startingPage "131" @default.
• W2169072424 abstract "Pretargeted radioimmunotherapy (PRIT) was evaluated using an antibody-streptavidin conjugate, followed by a biotin-galactose-human serum albumin clearing agent and 90Y-dodecane tetraacetic acid (DOTA)-biotin as the final step for therapy. The objective was to develop a clinical protocol that could show an improved tumor-to-red marrow therapeutic ratio compared with conventional radioimmunotherapy (RIT) and at the same time preserve the efficiency of tumor targeting.Forty-three patients with adenocarcinomas reactive to NR-LU-10 murine monoclonal antibody received the 3 components. Doses and timing parameters were varied to develop an optimized schema. In some patients, the conjugate was radiolabeled with 186Re as an imaging tracer to assess biodistribution of the conjugate and effectiveness of the clearing agent. 111In-DOTA-biotin was coinjected with 90Y-DOTA-biotin for quantitative imaging. Safety, biodistribution, pharmacokinetics, dosimetry, and antiglobulin formation were evaluated.The optimal schema was defined as a conjugate dose of 125 microg/mL plasma volume followed at 48 h by a clearing agent in a 10:1 molar ratio of clearing agent to serum conjugate. The therapeutic third step was 0.5 mg radiobiotin administered 24 h later. No significant adverse events were observed after administration of any of the components. The mean tumor-to-marrow absorbed dose ratio when using the optimized PRIT schema was 63:1, compared with a 6:1 ratio reported previously for conventional RIT. Antiglobulin to murine antibody and to streptavidin developed in most patients.This initial study confirmed that the PRIT approach is safe and feasible and achieved a higher therapeutic ratio than that achieved with conventional RIT using the same antibody." @default.
• W2169072424 created "2016-06-24" @default.
• W2169072424 creator A5003924924 @default.
• W2169072424 creator A5022960930 @default.
• W2169072424 creator A5023589038 @default.
• W2169072424 creator A5026578434 @default.
• W2169072424 creator A5026941412 @default.
• W2169072424 creator A5048985521 @default.
• W2169072424 creator A5059666930 @default.
• W2169072424 creator A5061265799 @default.
• W2169072424 creator A5085143914 @default.
• W2169072424 date "2000-01-01" @default.
• W2169072424 modified "2023-09-27" @default.
• W2169072424 title "Clinical optimization of pretargeted radioimmunotherapy with antibody-streptavidin conjugate and 90Y-DOTA-biotin." @default.
• W2169072424 cites W1606780680 @default.
• W2169072424 cites W1779429182 @default.
• W2169072424 cites W1952970584 @default.
• W2169072424 cites W1986239168 @default.
• W2169072424 cites W2076668534 @default.
• W2169072424 cites W2094555746 @default.
• W2169072424 cites W2114926334 @default.
• W2169072424 cites W2125814580 @default.
• W2169072424 cites W2222777425 @default.
• W2169072424 cites W2313535999 @default.
• W2169072424 cites W2411059694 @default.
• W2169072424 cites W2411175330 @default.
• W2169072424 cites W2417086497 @default.
• W2169072424 cites W2418548227 @default.
• W2169072424 cites W2463381696 @default.
• W2169072424 cites W945742090 @default.
• W2169072424 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10647616" @default.
• W2169072424 hasPublicationYear "2000" @default.
• W2169072424 type Work @default.
• W2169072424 sameAs 2169072424 @default.
• W2169072424 citedByCount "58" @default.
• W2169072424 countsByYear W21690724242012 @default.
• W2169072424 countsByYear W21690724242013 @default.
• W2169072424 countsByYear W21690724242014 @default.
• W2169072424 countsByYear W21690724242015 @default.
• W2169072424 countsByYear W21690724242016 @default.
• W2169072424 countsByYear W21690724242017 @default.
• W2169072424 countsByYear W21690724242018 @default.
• W2169072424 countsByYear W21690724242019 @default.
• W2169072424 countsByYear W21690724242020 @default.
• W2169072424 countsByYear W21690724242021 @default.
• W2169072424 countsByYear W21690724242022 @default.
• W2169072424 countsByYear W21690724242023 @default.
• W2169072424 crossrefType "journal-article" @default.
• W2169072424 hasAuthorship W2169072424A5003924924 @default.
• W2169072424 hasAuthorship W2169072424A5022960930 @default.
• W2169072424 hasAuthorship W2169072424A5023589038 @default.
• W2169072424 hasAuthorship W2169072424A5026578434 @default.
• W2169072424 hasAuthorship W2169072424A5026941412 @default.
• W2169072424 hasAuthorship W2169072424A5048985521 @default.
• W2169072424 hasAuthorship W2169072424A5059666930 @default.
• W2169072424 hasAuthorship W2169072424A5061265799 @default.
• W2169072424 hasAuthorship W2169072424A5085143914 @default.
• W2169072424 hasConcept C134306372 @default.
• W2169072424 hasConcept C159654299 @default.
• W2169072424 hasConcept C178790620 @default.
• W2169072424 hasConcept C185592680 @default.
• W2169072424 hasConcept C197336794 @default.
• W2169072424 hasConcept C197404232 @default.
• W2169072424 hasConcept C202751555 @default.
• W2169072424 hasConcept C203014093 @default.
• W2169072424 hasConcept C2776146153 @default.
• W2169072424 hasConcept C2776190903 @default.
• W2169072424 hasConcept C2777807558 @default.
• W2169072424 hasConcept C2778204606 @default.
• W2169072424 hasConcept C2779931791 @default.
• W2169072424 hasConcept C2989005 @default.
• W2169072424 hasConcept C33923547 @default.
• W2169072424 hasConcept C542903549 @default.
• W2169072424 hasConcept C55493867 @default.
• W2169072424 hasConcept C71924100 @default.
• W2169072424 hasConcept C98274493 @default.
• W2169072424 hasConceptScore W2169072424C134306372 @default.
• W2169072424 hasConceptScore W2169072424C159654299 @default.
• W2169072424 hasConceptScore W2169072424C178790620 @default.
• W2169072424 hasConceptScore W2169072424C185592680 @default.
• W2169072424 hasConceptScore W2169072424C197336794 @default.
• W2169072424 hasConceptScore W2169072424C197404232 @default.
• W2169072424 hasConceptScore W2169072424C202751555 @default.
• W2169072424 hasConceptScore W2169072424C203014093 @default.
• W2169072424 hasConceptScore W2169072424C2776146153 @default.
• W2169072424 hasConceptScore W2169072424C2776190903 @default.
• W2169072424 hasConceptScore W2169072424C2777807558 @default.
• W2169072424 hasConceptScore W2169072424C2778204606 @default.
• W2169072424 hasConceptScore W2169072424C2779931791 @default.
• W2169072424 hasConceptScore W2169072424C2989005 @default.
• W2169072424 hasConceptScore W2169072424C33923547 @default.
• W2169072424 hasConceptScore W2169072424C542903549 @default.
• W2169072424 hasConceptScore W2169072424C55493867 @default.
• W2169072424 hasConceptScore W2169072424C71924100 @default.
• W2169072424 hasConceptScore W2169072424C98274493 @default.
• W2169072424 hasIssue "1" @default.
• W2169072424 hasLocation W21690724241 @default.
• W2169072424 hasOpenAccess W2169072424 @default.

• next